Merz unveils 'Make Your Mark' campaign

Share this article:
A new patient advocacy campaign called “Make Your Mark” was launched April 14 on behalf of Merz Pharmaceuticals, maker of orphan drug Xeomin, a botulinum toxin type A free from accessory proteins. The online effort features the testimonials of national spokespeople—including 2010 Mrs. North Carolina, Dawn Brinkley, and opera singer, writer and actress, Hallie Neil—as well as the personal experiences of people living with cervical dystonia or blepharospasm.
Though the drug has been used abroad since 2005, Xeomin was approved in the US in 2010 for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain, and to treat abnormal spasms of the eyelids in adults who have had prior treatment with Botox. Administered as an injectible, Xeomin works to decrease muscle activity, which allows muscles to function more normally for patients diagnosed with either of these conditions.
The web-based campaign was developed by New York agency Medical Dynamics (the public relations AOR), in close partnership with Merz Pharmaceuticals, according to the company's director of marketing, Robert Yanez. This campaign will continue into 2012 and is one of “several initiatives designed to raise awareness of cervical dystonia and blepharospasm and encourage patient dialogue” by Merz Pharmaceuticals, says Yanez.
On the overall objective of the campaign, Yanez explains: “With the help of patient advocates, ‘Make Your Mark' celebrates the inspirational stories of people living with blepharospasm or cervical dystonia, also known as spasmodic torticollis, and aims to raise awareness of these often debilitating conditions.”
Share this article:

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...